Inhibition of aldose reductase and sorbitol accumulation by dietary rutin

Current Science

Volumn 101, Issue 9, 2011, Pages 1191-1197

  Reddy, G Bhanuprakash ^a   Muthenna, P ^a   Akileshwari, C ^a   Saraswat, Megha ^a   Petrash, J Mark ^b  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Aldehyde reductase; Aldose reductase; Diabetic complications; Rutin; Sorbitol

Indexed keywords

ANIMALIA;

EID: 84856449758     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414, 813-820.
2. Kinoshita, J. H., A thirty-year journey in the polyol pathway. Exp. Eye Res., 1990, 50, 567-573.
3. Bhatnagar, A. and Srivastava, S. K., Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. Biochem. Med. Metab. Biol., 1992, 48, 91-121.
4. Kador, P. F., Robison, W. G. and Kinoshita, J. H., The pharmacology of aldose reductase inhibitors. Annu. Rev. Pharmacol. Toxicol., 1985, 25, 691-714.
5. Pfeifer, M. A., Schumer, M. P. and Gelber, D. A., Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes, 1997, 46, S82-S89.
6. Raskin, P. and Rosenstock, J., Aldose reductase inhibitors and diabetic complications. Am. J. Med., 1987, 83, 298-306.
7. Jaspan, J. B., Towle, V. L., Maselli, R. and Herold, K., Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism, 1986, 35, 83-92.
8. Foppiano, M. and Lombardo, G., Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet, 1997, 349, 399-400.
9. Srivastava, S. K., Petrash, J. M., Sadana, I. J., Ansari, N. H. and Partridge, C. A., Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors. Curr. Eye Res., 1982, 2, 407-410.
10. Spite, M. et al., Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem. J., 2007, 405, 95-105.
11. Hyndman, D. J. and Flynn, T. G., Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim. Biophys. Acta, 1998, 1399, 198-202.
12. Crosas, B., Hyndman, D. J., Gallego, O., Martras, S., Pare, S. X., Flynn, T. G. and Farre, S. J., Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J., 2003, 373, 973-979.
13. Suryanarayana, P., Kumar, P. A., Saraswat, M., Petrash, J. M. and Reddy, G. B., Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract. Mol. Vis., 2004, 10, 148-154.
14. Suryanarayana, P., Saraswat, M., Mrudula, M., Krishna, T. P., Krishnaswamy, K. and Reddy, G. B., Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest. Ophthalmol. Vis. Sci., 2005, 46, 2092-2099.
15. Suryanarayana, P., Saraswat, M., Petrash, J. M. and Reddy, G. B., Emblica officinalis and its enriched tannoids delay streptozotocininduced diabetic cataract in rats. Mol. Vis., 2007, 24, 1291-1297.
16. Mrudula, T., Suryanarayana, P., Srinivas, P. N. and Reddy, G. B., Effect of curcumin on hyperglycaemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Biochem. Biophys. Res. Commun., 2007, 21, 528-532.
17. Saraswat, M., Muthenna, P., Suryanarayana, P., Petrash, J. M. and Reddy, G. B., Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac. J. Clin. Nutr., 2008, 17, 58-65.
18. Muthenna, P., Suryanarayana, P., Gunda, S., Petrash, J. M. and Reddy, G. B., Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance. FEBS Lett., 2009, 583, 3637-3642.
19. Saraswat, M. et al., Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. Mol. Vis., 2010, 16, 1525-1537.
20. Kawanishi, K., Ueda, H. and Moriyasu, M., Aldose reductase inhibitors from the nature. Curr. Med. Chem., 2003, 10, 1353-1374.
21. Zenon 3rd, G. J., Abobo, C. V., Carter, B. L. and Ball, D. W., Potential use of aldose reductase inhibitors to prevent diabetic complications. Clin. Pharm., 1990, 9, 446-457.
22. Fernández, M., Caballero, J., Helguera, A. M., Castro, E. A. and González, M. P., Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds. Bioorg. Med. Chem., 2005, 13, 3269-3277.
23. Matsuda, H., Morikawa, T., Toguchida, I. and Yoshikawa, M., Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem. Pharm. Bull, Tokyo, 2005, 50, 788-795.
24. Varma, S. D., Mikuni, I. and Kinoshita, J. H., Flavonoids as inhibitors of lens aldose reductase. Science, 1975, 188, 1215-1216.
25. Petrash, J. M., Harter, T. M., Devine, C. S., Olins, P. O., Bhatnagar, A., Liu, S. and Srivastava, S. K., Involvement of cysteine residues in catalysis and inhibition of human aldose reductase: site-directed mutagenesis of Cys-80, -298, and -303. J. Biol. Chem., 1992, 267, 24833-24840.
26. Daly, A. K. and Mantle, T. J., Purification and characterization of the multiple forms of aldehyde reductase in ox kidney. Biochem. J., 1982, 205, 373-380.
27. Malon, J. I., Knox, G., Benford, S. and Tedesco, T. A., Red cell sorbitol an indicator of diabetic control. Diabetes, 1980, 29, 861-864.
28. Florek, E., Ignatowicz, E., Wrzosek, J. and Piekoszewski, W., Effect of rutin on total antioxidant status of rats exposed to cigarette smoke. Pharmacol. Rep., 2005, 57, 84-89.
29. Undeǧer, U., Aydin, S., Başaran, A. A. and Başaran, N., The modulating effects of quercetin and rutin on the mitomycin C induced DNA damage. Toxicol. Lett., 2004, 151, 143-149.
30. Sheu, J. R., Hsiao, G., Chou, P. H., Shen, M. Y. and Chou, D. S., Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J. Agric. Food Chem., 2004, 52, 4414-4418.
31. Bhatnagar, A., Liu, S. Q., Das, B., Ansari, N. H. and Srivastava, S. K., Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors. Biochem. Pharmacol., 1990, 39, 1115-1124.
32. Bohren, K. M. and Grimshaw, C. E., The sorbinil trap: A predicted dead-end complex confirms the mechanism of aldose reductase inhibition. Biochemistry, 2000, 39, 9967-9997.
33. Morrison, A. D., Clements, R. S. and Winegord, A. I., Effects of elevated glucose concentration on the metabolism of the aorta wall. J. Clin. Invest., 1972, 51, 3114-3123.
34. Reddy, G. B., Satyanarayana, A., Balakrishna, N., Ayyagari, R., Padma, M., Viswanath, K. and Petrash, J. M., Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol. Vis., 2008, 14, 593-601.
35. Chung, S. S., Ho, E. C., Lam, K. S. and Chung, S. K., Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol., 2003, 14, S233-S236.
36. Pashikanti, S., de Alba, D. R., Boissonneault, G. A. and Cervantes-Laurean, D., Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products. Free Radical Biol. Med., 2010, 48, 656-663.
37. Muthenna, P., Akileshwari, C., Saraswat, M. and Reddy, G. B., Inhibition of advanced glycation end product formation on eye lens protein by rutin. Br. J. Nutr., 2011, August 25, 1-9 [Epub ahead of print].